The nucleolus: An emerging target for cancer therapy

Trends in Molecular Medicine

Volumn 19, Issue 11, 2013, Pages 643-654

  Hein, Nadine ^a,b   Hannan, Katherine M ^a,b   George, Amee J ^a,b,c   Sanij, Elaine ^a,b   Hannan, Ross D ^a,b,c,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Cancer therapy; Nucleolar stress; Nucleolus; P53; Ribosomal gene transcription; RNA polymerase I inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CAMPTOTHECIN; CISPLATIN; CX 5461; DACTINOMYCIN; DOXORUBICIN; ELLIPTICINE; EVEROLIMUS; EXEMESTANE; FLAVOPIRIDOL; FLUOROURACIL; HOMOHARRINGTONINE; IRINOTECAN; MITOMYCIN; MITOXANTRONE; OXALIPLATIN; PROTEIN P53; QUARFLOXIN; RAPAMYCIN; RNA; ROSCOVITINE; TEMSIROLIMUS; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANTINEOPLASTIC ACTIVITY; BILIARY TRACT CANCER; BIOGENESIS; BLADDER CANCER; BREAST CANCER; CANCER THERAPY; CARCINOID; CELL ACTIVITY; CELL FUNCTION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DRUG INHIBITION; ESOPHAGUS CANCER; EWING SARCOMA; GAIN OF FUNCTION MUTATION; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIVER CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELOID LEUKEMIA; MYELOMA; NEOPLASM; NEPHROBLASTOMA; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEOLUS; OVARY CANCER; OVARY SARCOMA; PANCREAS CANCER; PROSTATE CANCER; REVIEW; RIBOSOME; RNA PROCESSING; RNA SYNTHESIS; STOMACH CANCER; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; TESTIS CANCER; THYROID CANCER; TRANSCRIPTION INITIATION; TUBEROUS SCLEROSIS; UTERINE CERVIX CANCER;

CANCER THERAPY; NUCLEOLAR STRESS; NUCLEOLUS; P53; RIBOSOMAL GENE TRANSCRIPTION; RNA POLYMERASE I INHIBITOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL NUCLEOLUS; DNA, RIBOSOMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS;

EID: 84886952042     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.07.005     Document Type: Review

References (130)

1. Wagner R. Einige Bemerkungen und Fragen über das Keimbläschen (vesicular germinativa). Müller's Archiv. Anat. Physiol. Wissenschaft. Med. 1835, 373-377.
2. Valentin G. Repertorium für Anatomie und Physiologie. Verlag Veit Comp. Berl. 1836, 1:1-293.
3. Heitz E. Nukleolar und chromosomen in der gattung. Vicia Planta 1931, 15:495-505.
4. McClintock B. The relationship of a particular chromosomal element to the development of the nucleoli in Zea mays. Z. Zellforsch. Mikrosk. 1934, 21:294-398.
5. Pederson T. The nucleolus. Cold Spring Harb. Perspect. Biol. 2011, 3:1-15.
6. Heix J., et al. Mitotic silencing of human rRNA synthesis: inactivation of the promoter selectivity factor SL1 by cdc2/cyclin B-mediated phosphorylation. EMBO J. 1998, 17:7373-7381.
7. Derenzini M., et al. What the nucleolus says to a tumour pathologist. Histopathology 2009, 54:753-762.
8. Boulon S., et al. The nucleolus under stress. Mol. Cell 2010, 40:216-227.
9. Boisvert F.M., et al. The multifunctional nucleolus. Nat. Rev. Mol. Cell Biol. 2007, 8:574-585.
10. Wade M., et al. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 2013, 13:83-96.
11. Deisenroth C., Zhang Y. Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene 2010, 29:4253-4260.
12. Zhang Y., Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009, 16:369-377.
13. Bywater M.J., et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 2012, 22:51-65.
14. Pederson T. The plurifunctional nucleolus. Nucleic Acids Res. 1998, 26:3871-3876.
15. Andersen J.S., et al. Directed proteomic analysis of the human nucleolus. Curr. Biol. 2002, 12:1-11.
16. Ahmad Y., et al. NOPdb: nucleolar proteome database - 2008 update. Nucleic Acids Res. 2009, 37:181-184.
17. Olson M.O.J. Sensing cellular stress: another new function for the nucleolus?. Sci. STKE 2004, 2004:pe10.
18. Olson M.O.J., Dundr M. The moving parts of the nucleolus. Histochem. Cell Biol. 2005, 123:203-216.
19. Colombo E., et al. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat. Cell Biol 2002, 4:529-533.
20. Daniely Y., et al. Stress-dependent nucleolin mobilization mediated by p53-nucleolin complex formation. Mol. Cell. Biol. 2002, 22:6014-6022.
21. Gjerset R.A., Bandyopadhyay K. Regulation of p14ARF through subnuclear compartmentalization. Cell Cycle 2006, 5:686-690.
22. Shav-Tal Y., et al. Dynamic sorting of nuclear components into distinct nucleolar caps during transcriptional inhibition. Mol. Biol. Cell 2005, 16:2395-2413.
23. Rubbi C.P., Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 2003, 22:6068-6077.
24. Boisvert F.M., et al. A quantitative proteomics analysis of subcellular proteome localization and changes induced by DNA damage. Mol. Cell. Proteomics 2010, 9:457-470.
25. Boisvert F.M., Lamond A.I. p53-Dependent subcellular proteome localization following DNA damage. Proteomics 2010, 54:4087-4097.
26. Emmott E., et al. Elucidation of the avian nucleolar proteome by quantitative proteomics using SILAC and changes in cells infected with the coronavirus infectious bronchitis virus. Proteomics 2010, 10:3558-3562.
27. Lam Y.W., et al. Proteomics analysis of the nucleolus in adenovirus-infected cells. Mol. Cell. Proteomics 2010, 9:117-130.
28. Moore H.M., et al. Quantitative proteomics and dynamic imaging of the nucleolus reveals distinct responses to UV and ionizing radiation. Mol. Cell. Proteomics 2011, 10:1-15.
29. Momand J., et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
30. Oliner J.D., et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993, 362:857-860.
31. Haupt Y., et al. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
32. Kubbutat M.H., et al. Regulation of p53 stability by Mdm2. Nature 1997, 387:299-303.
33. Lee J.T., Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 2010, 17:86-92.
34. Marechal V., et al. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol. Cell. Biol. 1994, 14:7414-7420.
35. Fontoura B.M., et al. p53 is covalently linked to 5.8S rRNA. Mol. Cell. Biol. 1992, 12:5145-5151.
36. Lohrum M.A., et al. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003, 3:577-587.
37. Zhang Y.P., et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 2003, 23:8902-8912.
38. Bhat K.P., et al. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 2004, 23:2402-2412.
39. Dai M.S., Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 2004, 279:44475-44482.
40. Dai M.S., et al. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol. Cell. Biol. 2004, 24:7654-7668.
41. Yadavilli S., et al. Ribosomal protein S3: a multi-functional protein that interacts with both p53 and MDM2 through its KH domain. DNA Repair (Amst.) 2009, 8:1215-1224.
42. Macias E., et al. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 interaction. Cancer Cell 2010, 18:231-243.
43. Li M., Gu W. A critical role for noncoding 5S rRNA in regulating Mdmx stability. Mol. Cell 2011, 43:1023-1032.
44. Chen D., et al. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene 2007, 26:5029-5037.
45. Fumagalli S., et al. Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. Genes Dev. 2012, 26:1028-1040.
46. Zhu Y., et al. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol. Cell 2009, 35:316-326.
47. Sasaki M., et al. Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nat. Med. 2011, 17:944-951.
48. Takagi M., et al. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell 2005, 123:49-63.
49. Ofir-Rosenfeld Y., et al. Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Mol. Cell 2008, 32:180-189.
50. Sundqvist A., et al. Regulation of nucleolar signalling to p53 through NEDDylation of L11. EMBO Rep. 2009, 10:1132-1139.
51. Fumagalli S., et al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat. Cell. Biol. 2009, 11:501-508.
52. Ma H., Pederson T. The nucleolus stress response is coupled to an ATR-Chk1-mediated G2 arrest. Mol. Biol. Cell 2013, 24:1334-1342.
53. Bywater M.J., et al. Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat. Rev. Cancer 2013, 13:299-314.
54. Hannan K.M., et al. Dysregulation of RNA polymerase I transcription during disease. Biochim. Biophys. Acta 2013, 1829:342-360.
55. Falini B., et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007, 92:519-532.
56. Falini B., et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007, 109:874-885.
57. Grisendi S., et al. Nucleophosmin and cancer. Nat. Rev. Cancer 2006, 6:493-505.
58. Colombo E., et al. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene 2011, 30:2595-2609.
59. Ma H., Pederson T. Nucleophosmin is a binding partner of nucleostemin in human osteosarcoma cells. Mol. Biol. Cell 2008, 19:2870-2875.
60. Li Z., et al. Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18794-18799.
61. Liu H.T., Yung B.Y. In vivo interaction of nucleophosmin/B23 and protein C23 during cell cycle progression in HeLa cells. Cancer Lett. 1999, 144:45-54.
62. Bertwistle D., et al. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol. Cell. Biol. 2004, 24:985-996.
63. Kurki S., et al. Nucleophosmin, HDM2 and p53: players in UV damage incited nucleolar stress response. Cell Cycle 2004, 3:976-979.
64. Murano K., et al. Transcription regulation of the rRNA gene by a multifunctional nucleolar protein, B23/nucleophosmin, through its histone chaperone activity. Mol. Cell. Biol. 2008, 28:3114-3126.
65. Burger K., et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J. Biol. Chem. 2010, 285:12416-12425.
66. Drygin D., et al. The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. Annu. Rev. Pharmacol. Toxicol. 2010, 50:131-156.
67. Sun X.X., et al. 5-Fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J. Biol. Chem. 2007, 282:8052-8059.
68. Andrews W.J., et al. Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription. J. Biol. Chem. 2013, 288:4567-4582.
69. Mathe G., et al. Methoxy-9-ellipticine lactate. 3. Clinical screening: its action in acute myeloblastic leukaemia. Eur. J. Clin. Biol. Res. 1970, 15:541-545.
70. Drygin D., et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res. 2009, 69:7653-7661.
71. Fetherston J., et al. Processing of the external transcribed spacer of murine rRNA and site of action of actinomycin D. Nucleic Acids Res. 1984, 12:7187-7198.
72. Sobell H.M. Actinomycin and DNA transcription. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:5328-5331.
73. Drygin D., et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 2011, 71:1418-1430.
74. Godley L.A., Larson R.A. Therapy-related myeloid leukemia. Semin. Oncol. 2008, 35:418-429.
75. Vassilev L.T., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
76. Tovar C., et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 2013, 73:2587-2597.
77. Patnaik A., et al. Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors. AACR Annu. Meet. 2013, LB-20.
78. Dang C.V. MYC on the path to cancer. Cell 2012, 149:22-35.
79. van Koningsbruggen S., et al. High-resolution whole-genome sequencing reveals that specific chromatin domains from most human chromosomes associate with nucleoli. Mol. Biol. Cell 2010, 21:3735-3748.
80. Nemeth A., et al. Initial genomics of the human nucleolus. PLoS Genet. 2010, 6:11.
81. Norton J.T., et al. The perinucleolar compartment is directly associated with DNA. J. Biol. Chem. 2009, 284:4090-4101.
82. Zhang L.F., et al. Perinucleolar targeting of the inactive X during S phase: evidence for a role in the maintenance of silencing. Cell 2007, 129:693-706.
83. Hein N., et al. Inhibition of RNA polymerase I transcription by CX-5461 as a therapeutic strategy for the cancer-specific activation of p53 in MLL-rearranged acute myeloid leukaemias. Blood 2011, American Society of Hematology, Abstract 118.
84. Stefanovsky V.Y., et al. An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol. Cell 2001, 8:1063-1073.
85. Zhao J., et al. ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth. Mol. Cell 2003, 11:405-413.
86. Sears R., et al. Ras enhances Myc protein stability. Mol. Cell 1999, 3:169-179.
87. Hannan K.M., et al. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol. Cell. Biol. 2003, 23:8862-8877.
88. Chan J.C., et al. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. Sci. Signal. 2011, 4:ra56.
89. Grandori C., et al. c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nat. Cell Biol. 2005, 7:311-318.
90. Arabi A., et al. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat. Cell Biol. 2005, 7:303-310.
91. Poortinga G., et al. MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO J. 2004, 23:3325-3335.
92. Poortinga G., et al. c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation. Nucleic Acids Res. 2011, 39:3267-3281.
93. Schlosser I., et al. A role for c-Myc in the regulation of ribosomal RNA processing. Nucleic Acids Res. 2003, 31:6148-6156.
94. Zeller K.I., et al. Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation. J. Biol. Chem. 2001, 276:48285-48291.
95. van Riggelen J., et al. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat. Rev. Cancer 2010, 10:301-309.
96. Gomez-Roman N., et al. Direct activation of RNA polymerase III transcription by c-Myc. Nature 2003, 421:290-294.
97. Kenneth N.S., et al. TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14917-14922.
98. Tsai R.Y.L., McKay R.D.G. A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev. 2002, 16:2991-3003.
99. Romanova L., et al. Critical role of nucleostemin in pre-rRNA processing. J. Biol. Chem. 2009, 284:4968-4977.
100. Bakshi R., et al. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes. J. Cell Sci. 2008, 121:3981-3990.
101. Delloye-Bourgeois C., et al. Nucleolar localization of a netrin-1 isoform enhances tumor cell proliferation. Sci. Signal. 2012, 5:ra57.
102. Bartek J., et al. A common path to tumor growth. Oncol. Rep. 1996, 3:237-240.
103. Chinnam M., Goodrich D.W. RB1, development, and cancer. Curr. Top. Dev. Biol. 2011, 94:129-169.
104. Cavanaugh A.H., et al. Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature 1995, 374:177-180.
105. Hannan K.M., et al. Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1. Oncogene 2000, 19:4988-4999.
106. Hannan K.M., et al. RNA polymerase I transcription in confluent cells: Rb downregulates rDNA transcription during confluence-induced cell cycle arrest. Oncogene 2000, 19:3487-3497.
107. White R.J., et al. Repression of RNA polymerase III transcription by the retinoblastoma protein. Nature 1996, 382:88-90.
108. Chu W.M., et al. RNA polymerase III transcription repressed by Rb through its interactions with TFIIIB and TFIIIC2. J. Biol. Chem. 1997, 272:14755-14761.
109. Zhai W., Comai L. Repression of RNA polymerase I transcription by the tumor suppressor p53. Mol. Cell. Biol. 2000, 20:5930-5938.
110. Crighton D., et al. p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB. EMBO J. 2003, 22:2810-2820.
111. Budde A., Grummt I. p53 represses ribosomal gene transcription. Oncogene 1999, 18:1119-1124.
112. Stein T., et al. Several regions of p53 are involved in repression of RNA polymerase III transcription. Oncogene 2002, 21:5540-5547.
113. Brady S.N., et al. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol. Cell. Biol. 2004, 24:9327-9338.
114. Ayrault O., et al. Human tumor suppressor p14ARF negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation. Oncogene 2006, 25:7577-7586.
115. Savkur R.S., Olson M.O. Preferential cleavage in pre-ribosomal RNA byprotein B23 endoribonuclease. Nucleic Acids Res. 1998, 26:4508-4515.
116. Apicelli A.J., et al. A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function. Mol. Cell. Biol. 2008, 28:1068-1080.
117. Young D.W., et al. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 2007, 445:442-446.
118. Kruhlak M., et al. The ATM repair pathway inhibits RNA polymerase I transcription in response to chromosome breaks. Nature 2007, 447:730-734.
119. Blyth K., et al. Runx2 in normal tissues and cancer cells: a developing story. Blood Cells Mol. Dis. 2010, 45:117-123.
120. Ali S.A., et al. A RUNX2-HDAC1 co-repressor complex regulates rRNA gene expression by modulating UBF acetylation. J. Cell Sci. 2012, 125:2732-2739.
121. Zaidi S.K., et al. Epigenetic mechanisms in leukemia. Adv. Biol. Regul. 2012, 52:369-376.
122. Rey J.P., et al. Induction and removal of interstrand crosslinks in the ribosomal RNA genes of lymphoblastoid cell lines from patients with Fanconi anemia. Mutat. Res. 1993, 289:171-180.
123. Jordan P., Carmo-Fonseca M. Cisplatin inhibits synthesis of ribosomal RNA in vivo. Nucleic Acids Res. 1998, 26:2831-2836.
124. Kidani Y., et al. Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers. Gann 1980, 71:637-643.
125. Alberts D.S., et al. Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug. Cancer Chemother. Pharmacol. 1980, 5:11-15.
126. Di Marco A., et al. Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother. Rep. 1 1969, 53:33-37.
127. Gallo R.C., et al. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst. 1971, 46:789-795.
128. Mahajan P.B. Modulation of transcription of rRNA genes by rapamycin. Int. J. Immunopharmacol. 1994, 16:711-721.
129. Ghoshal K., Jacob S.T. An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem. Pharmacol. 1997, 53:1569-1575.
130. Hsu B. The use of herbs as anticancer agents. Am. J. Chin. Med. 1980, 8:301-306.